BIO-FD&CLtd Valuation

Q: What is the Fair Price of A251120 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A251120 (₩13540) is trading below our estimate of [[fair value]] (₩17843.89)

Is A251120 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A251120 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A251120 (₩13540) is trading below our estimate of fair value (₩17843.89)

Significantly Below Fair Value: A251120 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A251120?

Key metric: As A251120 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A251120. This is calculated by dividing A251120's market cap by their current earnings.
What is A251120's PE Ratio?
PE Ratio	23.1x
Earnings	₩5.10b
Market Cap	₩117.74b

A251120 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.7x
Enterprise Value/EBITDA	12.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A251120's PE Ratio compare to its peers?

The above table shows the PE ratio for A251120 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18x
A049960 Cell Biotech	7.1x	n/a	₩92.7b
A191420 TegoScience	35.9x	n/a	₩120.3b
A109960 AP Healthcare	17.8x	n/a	₩95.0b
A182400 NKMAX	11x	n/a	₩172.7b
A251120 BIO-FD&CLtd	23.1x	n/a	₩117.7b

Price-To-Earnings vs Peers: A251120 is expensive based on its Price-To-Earnings Ratio (23.1x) compared to the peer average (18x).

Price to Earnings Ratio vs Industry

How does A251120's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A251120 is good value based on its Price-To-Earnings Ratio (23.1x) compared to the Asian Biotechs industry average (31.5x).

Price to Earnings Ratio vs Fair Ratio

What is A251120's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A251120 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	23.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A251120's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

0.9%

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

-5.8%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

1.7%

-39.0%